REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming ophthalmology conferences.
Conference Details:
BTIG 3rd Annual Ophthalmology Day
Format: Fireside Chat
Date: Monday, November 27, 2023
Time: 4:30 p.m. ET
Location: Virtual
Ashvattha’s Co-Founder, President, and Chief Executive Officer, Jeffrey Cleland, Ph.D., and Chief Financial Officer, Paul Cayer, will be available for one-on-one meetings. If you are interested in a meeting, please contact your BTIG representative.
Ophthalmology Innovation Summit (OIS) XIII
Format: Corporate Presentation
Date: Friday, December 1, 2023
Time: 1:01 p.m. PT
Location: Omni San Diego Hotel
Register for the summit here.
About Ashvattha Therapeutics
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. For more information, visit: www.avttx.com
Media Contact
Gloria Gasaatura
LifeSci Communications
ggasaatura@lifescicomms.com
646-970-4688
